HepeX B
Alternative Names: exbivirumab; HBV-AB17; HBV-AB19; HBV-XTL; Hepatitis B MAb-XTL; Human anti-HBV-XTL; libivirumab; Monoclonal antibody HBV-XTL; XTL-001Latest Information Update: 08 Feb 2017
At a glance
- Originator XTL Biopharmaceuticals
- Developer XTL Biopharmaceuticals; Yeda
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 31 Jul 2006 Discontinued - Phase-II for Hepatitis B prevention in European Union (Infusion)
- 31 Jul 2006 Discontinued - Phase-II for Hepatitis B prevention in World (Infusion)
- 31 Jul 2006 Discontinued - Phase-II for Hepatitis B treatment in Israel (Infusion)